维普期刊资源整合服务平台（V6.5）

69篇 您的检索式：作者名="Kuendgen"

选中清除导出查看参考文献查看引证文献引用追踪共4页首页上一页第1页下一页末页 /4 跳转

	题名	作者	年代	出处	被引量
1	The histone deacetylase( HDAC ) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia显示文摘	Kuendgen A Schmid M Schlenk R	2006	Cancer2006，106，：	1
2	Myelodysplastic syndromes in patients younger than age 50显示文摘	Kuendgen A Strupp C Aivado M	2006	J Clin Oncol2006，24，34：	1
3	Prospective validation of the WHO Proposals for the classication of the myelodysplastic syndromes 显示文摘	Garming U Strupp C kuendgen/A	2006	Haematologica2006，91，12：	1
4	Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes 显示文摘	MALCOVATI L GERMING U KUENDGEN A	2007	Clin Oncol2007，25，：	1
5	Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes显示文摘	Malcovati L Germing U Kuendgen A		0，，23：	1
6	Treatment of myelodys plastic syndromes with valproic acid alone or in combination with all trans retinoic acid显示文摘	Kuendgen A Stupp C Aivado M	2004	Blood2004，104，：	1
7	Differences in epidemiology of MDS between Western and Eastern countries:Ethnic differences or environmental influence 显示文摘	Kuendgen A Matsuda A Germing U	2007	Leuk Res2007，31，1：	1
8	The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia 显示文摘	KUENDGEN A SCHMID M SCHLENK R	2006	Cancer2006，106，1：	1
9	a Prognostic relevance of achieving cytoge- netic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemo- therapy显示文摘	Sebastian Balleisen Andrea Kuendgen Barbara Hildebrandt Rainer Haas	2009	Leukemia Research2009，33，：	1
10	Refractory anaemia with excess of blasts ( RAEB ) : analysis of reclassification according to the WHO proposals 显示文摘	Germing U Strupp C Kuendgen A	2006	Br J Haematol2006，132，：	1
11	Time-de- pendent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes显示文摘	Malcovati L Germing U Kuendgen A	2007	J Clin Oncol2007，25，23：	1
12	Emerging treatment strategies for acute mye- loid leukemia(AML) in the elderly显示文摘	Kuendgen A Germing U	2009	Cancer Treat Rev2009，35，2：	1
13	Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid显示文摘	Kuendgen A Strupp C Aivado M	2004	Blood2004，104，：	1
14	Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid 显示文摘	Kuendgen A Strupp C Aivado M	2004	Blood2004，104，：	1
15	Valproic acis achieves hugh response rates in patients with low-risk myelodysplastic syndromes显示文摘	Kuendgen A Schmid M Knipp S	2005	Blood2005，106，：	1
16	The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia显示文摘	Kuendgen A Schmid M Schlenk R	2006	Cancer2006，106，：	1
17	Results of a phase2 study of valproic acid alone or in combination with all-trans 3retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia显示文摘	Kuendgen A Knipp S Fox F	2005	Ann Hematol2005，84，1：	1
18	Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes显示文摘	Malcovati L Germing U Kuendgen A	2007	J Clin Oncol2007，25，23：	1
19	Valproic acis achieves hugh response rates in patients with low risk myelodysplastic syndromes 显示文摘	Kuendgen A Schmid M Knipp S	2005	Blood2005，106，：	1
20	Valproic acid for the treatment of myeloid malignancies显示文摘	KUENDGEN A GATTTERMANN N	2007	Cancer2007，110，5：	1

返回顶部每页显示：

共4页首页上一页第1页下一页末页 /4 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示